Dual inactivation of RB and p53 pathways in RAS-induced melanomas

Molecular and Cellular Biology

Volumn 21, Issue 6, 2001, Pages 2144-2153

  Bardeesy, Nabeel ^a   Bastian, Boris C ^b,c   Hezel, Aram ^a   Pinkel, Dan ^c   DePinho, Ronald A ^a   Chin, Lynda ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GENE PRODUCT; MONOPHENOL MONOOXYGENASE; PROTEIN P16; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; RETINOBLASTOMA PROTEIN;

ALLELE; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL TRANSFORMATION; CELL TYPE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; MELANOCYTE; MELANOMA; MOUSE; MUTATION; NONHUMAN; ONCOGENE C MYC; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; CDC25 PHOSPHATASE; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, RAS; IN SITU HYBRIDIZATION; MELANOMA; MICE; MICE, MUTANT STRAINS; PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RETINOBLASTOMA PROTEIN; S PHASE; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0034997650     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.6.2144-2153.2001     Document Type: Article

References (62)

1. Akslen, L. A., S. E. Monstad, B. Larsen, O. Straume, and D. Ogreid. 1998. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int. J. Cancer 79:91-95.
2. Albino, A. P., M. J. Vidal, N. S. McNutt, C. R. Shea, V. G. Prieto, D. M. Nanus, J. M. Palmer, and N. K. Hayward. 1994. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 4:35-45.
3. Alevizopoulos, K., J. Vlach, S. Hennecke, and B. Amati. 1997. Cyclin E and c-Myc promote cell proliferation in the presence of p161NK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J. 16:5322-5333.
4. Bastian, B. C., P. E. LeBoit, H. Hamm, E. B. Brocker, and D. Pinkel. 1998. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 58:2170-2175.
5. Berns, K., E. M. Hijmans, and R. Bernards. 1997. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene 15:1347-1356.
6. Bouchard, C., K. Thieke, A. Maier, R. Saffrich, J. Hanley-Hyde, W. Ansorge, S. Reed, P. Sicinski, J. Bartek, and M. Eilers. 1999. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 18:5321-5333.
7. Castresana, J. S., M. P. Rubio, J. J. Vazquez, M. Idoate, A. J. Sober, B. R. Seizinger, and R. L. Barnhill. 1993. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int. J. Cancer 55:562-565.
8. Chin, L., J. Pomerantz, D. Polsky, M. Jacobson, C. Cohen, C. Cordon-Cardo, J. W. Horner 2nd, and R. A. DePinho. 1997. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 11:2822-2834.
9. Dang, C. V. 1999. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Bio. 19:1-11.
10. de Stanchina, E., M. E. McCurrach, F. Zindy, S. Y. Shieh, G. Ferbeyre, A. V. Samuelson, C. Prives, M. F. Roussel, C. J. Sherr, and S. W. Lowe. 1998. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12: 2434-2442.
11. Eischen, C. M., J. D. Weber, M. F. Roussel, C. J. Sherr, and J. L. Cleveland. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:2658-2669.
12. Essner, R., C. T. Kuo, H. Wang, D. R. Wen, R. R. Turner, T. Nguyen, and D. S. Hoon. 1998. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer 82:309-316.
13. Felsher, D.W., and J. M. Bishop. 1999. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. USA 96:3940-4.
14. Galaktionov, K., X. Chen, and D. Beach. 1996. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382:511-517.
15. Grant, S. W., A. S. Kyshtoobayeva, T. Kurosaki, J. Jakowatz, and J. P. Fruehauf. 1998. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect. Prev. 22:185-194.
16. Greenberg, R. A., R. C. Allsopp, L. Chin, G. B. Morin, and R. A. DePinho. 1998. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene 16:1723-1730.
17. Greenblatt, M. S., W. P. Bennett, M. Hollstein, and C. C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
18. Hermeking, H., C. Rago, M. Schuhmacher, Q. Li, J. F. Barrett, A. J. Obaya, B. C. O'Connell, M. K. Mateyak, W. Tam, F. Kohlhuber, C. V. Dang, J. M. Sedivy, D. Eick, B. Vogelstein, and K. W. Kinzler. 2000. Identification of CDK4 as a target of c-MYC. Proc. Natl. Acad. Sci. USA 97:2229-2234.
19. Hoang, A. T., K. J. Cohen, J. F. Barrett, D. A. Bergstrom, and C. V. Dang. 1994. Participation of cyclin A in Myc-induced apoptosis. Proc. Natl. Acad. Sci. USA 91:6875-6879.
20. Hosokawa, Y., and A. Arnold. 1996. Cyclin D1/PRAD1 as a central target in oncogenesis. J. Lab. Clin. Med. 127:246-252.
21. Iritani, B. M., and R. N. Eisenman. 1999. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc. Natl. Acad. Sci. USA 96:13180-13185.
22. Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson, and R. A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7.
23. Kallioniemi, A., O. P. Kallioniemi, D. Sudar, D. Rutovitz, J. W. Gray, F. Waldman, and D. Pinkel. 1992. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-821.
24. Kamijo, T., S. Bodner, E. van de Kamp, D. H. Randle, and C. J. Sherr. 1999. Tumor spectrum in ARF-deficient mice. Cancer Res. 59:2217-2222.
25. Kamijo, T., E. van de Kamp, M. J. Chong, F. Zindy, J. A. Diehl, C. J. Sherr, and P. J. McKinnon. 1999. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res. 59:2464-2469.
26. Kamijo, T., J. D. Weber, G. Zambetti, F. Zindy, M. F. Roussel, and C. J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95:8292-8297.
27. Kamijo, T., F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. J. Sherr. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-659.
28. LaBaer, J., M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847-862.
29. Leone, G., J. DeGregori, R. Sears, L. Jakoi, and J. R. Nevins. 1997. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387:422-426.
30. Levy, N., E. Yonish-Rouach, M. Oren, and A. Kimchi. 1993. Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol. cell. Biol. 13:7942-7952.
31. Lloyd, A. C. 1998. Ras versus cyclin-dependent kinase inhibitors. Curr. Opin. Genet. Dev. 8:43-48.
32. Lubbe, J., M. Reichel, G. Burg, and P. Kleihues. 1994. Absence of p53 gene mutations in cutaneous melanoma. J. Investig. Dermatol. 102:819-821.
33. Malumbres, M., and A. Pellicer. 1998. RAS pathways to cell cycle control and cell transformation. Front. Biosci. 3:887-912.
34. Mangray, S., and T. C. King. 1998. Molecular pathobiology of pancreatic adenocarcinoma. Front. Biosci. 3:1148-1160.
35. Mateyak, M. K., A. J. Obaya, S. Adachi, and J. M. Sedivy. 1997. Phenotypes of c-Myc-deficient rat filbroblasts isolated by targeted homologous recombination. Cell Growth Differ. 8:1039-1048.
36. O'Hagan, R. C., M. Ohh, G. David, I. M. de Alboran, F. W. Alt, W. G. Kaelin, Jr., and R. A. DePinho. 2000. Myc-enhanced expression of Cull promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev. 14: 2185-2191.
37. Ory, D. S., B. A. Neugeboren, and R. C. Mulligan. 1996. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93:11400-11406.
38. Papp, T., M. Jafari, and D. Schiffmann. 1996. Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions. J. Cancer Res. Clin. Oncol. 122:541-548.
39. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
40. Quelle, D. E., F. Zindy, R. A. Ashmun, and C. J. Sherr. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
41. Radfar, A., I. Unnikrishnan, H. W. Lee, and R. A. DePinho. 1998. p19(Arf) induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation. Proc. Natl. Acad. Sci. USA 95:13194-13199.
42. Ragimov, N., A. Krauskopf, N. Navot, V. Rotter, M. Oren, and Y. Aloni. 1993. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8:1183-1193.
43. Rhim, K. J., S. I. Hong, W. S. Hong, S. Y. Lee, D. S. Lee, and J. J. Jang. 1994. Aberrant expression of p53 gene product in malignant melanoma. J. Korean Med. Sci. 9:376-381.
44. Ruas, M., and G. Peters. 1998. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophy. Acta 1378:115-77.
45. Russo, A. A., L. Tong, J. O. Lee, P. D. Jeffrey, and N. P. Pavletich. 1998. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumor suppressor p16INK4a. Nature 395:237-243.
46. Salgia, R., and A. T. Skarin. 1998. Molecular abnormalities in lung cancer. J. Clin. Oncol. 16:1207-1217.
47. Santoni-Rugiu, E., J. Falck, N. Mailand, J. Bartek, and J. Lukas. 2000. Involvement of Myc activity in a G1/S-promoting mechanism parallel to the pRb/E2F pathway. Mol. Cell. Biol. 20:3497-3509.
48. Schmitt, C. A., M. E. McCurrach, E. de Stanchina, R. R. Wallace-Brodeur, and S. W. Lowe. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13:2670-2677.
49. Serrano, M., H. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R. A. DePinho. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37.
50. Sharpless, N. E., and R. A. DePinho. 1999. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9:22-30.
51. Sparrow, L. E., R. Soong, H. J. Dawkins, B. J. Iacopetta, and P. J. Heenan. 1995. p53 gene mutation and expression in naevi and melanomas. Melanoma Res. 5:93-100.
52. Spotts, G. D., S. V. Patel, Q. Xiao, and S. R. Hann. 1997. Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins. Mol. Cell. Biol. 17:1459-1468.
53. Steiner, P., A. Philipp, J. Lukas, D. Godden-Kent, M. Pagano, S. Mittnacht, J. Bartek, and M. Eilers. 1995. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J. 14:4814-4826.
54. Stott, F. J., S. Bates, M. C. James, B. B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K. H. Vousden, and G. Peters. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
55. Sun, X. H., N. G. Copeland, N. A. Jenkins, and D. Baltimore. 1991. Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins. Mol. Cell. Biol. 11:5603-5611.
56. Vlach, J., S. Hennecke, K. Alevizopoulos, D. Conti, and B. Amati. 1996. Growth arrest by the cyclin-dependent kinase inhibitor p27Kipl is abrogated by c-Myc. EMBO J. 15:6595-6604.
57. Wolfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, P. E. De, T. Hankeln, z. B. K. H. Meyer, and D. Beach. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284.
58. Xiao, Q., G. Claassen, J. Shi, S. Adachi, J. Sedivy, and S. R. Hann. 1998. Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis. Genes Dev. 12:3803-3808.
59. Zerp, S. F., A. van Elsas, L. T. Peltenburg, and P. I. Schrier. 1999. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis. Br. J. Cancer 79:921-926.
60. Zhang, S., E. S. Ramsay, and B. A. Mock. 1998. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctrl. Proc. Natl. Acad. Sci. USA 95:2429-2434.
61. Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.
62. Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12: 2424-2433.